The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting the accelerating consolidation within the healthcare technology sector, Danaher has completed the acquisition of Masimo in a cash deal finalized at $9.5 billion. According to reports, the transaction resulted in the delisting of Masimo shares from the Nasdaq exchange, with shareholders receiving a fixed price of $180 per share. Masimo will now operate as a standalone subsidiary within Danaher’s Diagnostics segment, focusing on AI-enabled patient-monitoring technologies.
This acquisition positions Danaher more competitively against industry peers such as Thermo Fisher Scientific and Abbott Laboratories, as manufacturers increasingly prioritize AI integration in medical devices. Compared to previous sector deals, Masimo's valuation reflects a premium for remote sensing technologies that have seen surging demand. Per market data, Danaher’s expansion into this niche aims to diversify revenue streams beyond traditional laboratory services.
Shares of DHR stood at $180.79 (close June 11, 2026), having reached a session high of $184.13. Investors are now watching for the operational integration of Masimo and its impact on profit margins in upcoming quarters. Regarding the economic calendar, traders are monitoring the Fed's Barr speech and recent Chinese inflation data for their broader influence on global healthcare sector sentiment.
Update: Danaher has confirmed that its full-year 2026 financial guidance remains unchanged for now, as current figures do not yet account for Masimo's contribution. The company plans to provide an updated guidance outlook that includes Masimo following the release of its second-quarter earnings, while clarifying that Masimo will continue to operate under its existing brand as a wholly-owned subsidiary.